SEC Form 4 · accession 0001144204-17-033638
KIORA PHARMACEUTICALS INC · KPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brenda Mann
Officer — VP of Research & Development
Period of report
Jun 21, 2017
Accepted (ET)
Jun 22, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001372514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.35 | Jun 21, 2017 | A | 15,000 | A | — | Jun 21, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on June 21, 2018, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.